Alto Neuroscience, Inc. — Form 8-K
Filed July 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Alto Neuroscience conducted a registered direct offering on July 13, 2026, issuing 3,776,436 shares of common stock at $26.48/share via BofA Securities (lead), Stifel Nicolaus, William Blair, and others. Gross proceeds: ~$99.9M; net to company ~$94.5M after $1.46/share underwriting discount. Standard underwriting agreement with 60-day lock-up on officers/directors.
Why this rating
Secondary offering of ~$100M gross (180% of $55.2M market cap) provides substantial capital infusion for clinical/operational needs. Dilutive but material for a micro-cap biotech. Real estate is significant relative to company size.
See more from July 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.